Megan Cheah from The Business Times in Singapore recently spoke to Gordon Sanghera and Kathleen C. Barnes about our growing business in Asia and partnership with Singapore’s Precise-SG100K program. Southeast Asia is one of the most under-represented and diverse populations. By sequencing 10,000 multi-ancestry genomes, we aim to create more equity in healthcare and develop a rich library for a richer understanding of human DNA. Check out Megan's recent post and his article below.
#Genetics can tell you a whole lot about someone, but the technology in the field has not quite been accessible to startups and smaller companies. Enter Oxford Nanopore Technologies, a #DNA sequencing biotech firm listed on the London Stock Exchange and backed by both Temasek and GIC. The group's sequencing tech was used during Covid, when researchers needed to characterise the virus' genome to track its variants. The company is also participating in the Precise-SG100K research programme led by Ministry of Health (Singapore), aiming to sequence 10,000 genomes representing the Republic's multi-ethnic population. With Oxford Nanopore's more accessible tech, startups and SMEs can enter the genomic research space, said CEO Gordon Sanghera. Speaking to media in a roundtable along with Kathleen C. Barnes, he noted that initiatives in precision medicine rolled out in Singapore are likely to foster innovation in several fields, including healthcare and food industry contamination. He also spoke to The Business Times after the roundtable regarding the company's #financials, which are on-track to the company's Ebitda breakeven goal by end-2027. This was supported by Oxford Nanopore's half-year results just released on Tuesday. More in my story here: Many thanks to Gordon and Kathleen for speaking to me and accommodating the last-minute switch to Zoom! Really enjoyed learning about this field. #biotech
